AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Wednesday May 20 2020 its full year results for the year ended March 31 2020. The release will be issued at around 09:00.
This will be followed by a presentation by management at 10:00 by teleconference. The presentation material which will be referred to by management will be issued at around 09:00 and will also be available on the company’s website aftpharm.com.
To attend the conference call you will need to use the pre-registration link below. Once you have completed this you will be provided with dial in details and a unique pin code.
Registration Link: https://s1.c-conf.com/DiamondPass/10006166-invite.html
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO. For more information:
Investors:
Malcolm Tubby
CFO, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232
Email: malcolm@aftpharm.com
Media:
Richard Inder
The Project
Phone: 021 645 643
Email: richard@theproject.co.nz
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com
